DexCom, Inc. (NASDAQ:DXCM) Expected to Announce Earnings of $0.76 Per Share

Equities analysts expect DexCom, Inc. (NASDAQ:DXCMGet Rating) to report earnings per share of $0.76 for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for DexCom’s earnings, with estimates ranging from $0.54 to $1.07. DexCom also posted earnings per share of $0.76 during the same quarter last year. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that DexCom will report full-year earnings of $3.38 per share for the current fiscal year, with EPS estimates ranging from $3.11 to $3.96. For the next fiscal year, analysts anticipate that the firm will post earnings of $4.75 per share, with EPS estimates ranging from $3.90 to $5.85. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow DexCom.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.20). DexCom had a net margin of 8.23% and a return on equity of 12.51%. The business had revenue of $628.80 million for the quarter, compared to the consensus estimate of $623.97 million. During the same period in the prior year, the company earned $0.33 EPS. DexCom’s quarterly revenue was up 24.5% on a year-over-year basis.

Several research firms have commented on DXCM. Raymond James decreased their target price on shares of DexCom from $538.00 to $486.00 in a research report on Friday. Morgan Stanley reduced their price target on shares of DexCom from $570.00 to $514.00 and set an “equal weight” rating for the company in a research note on Friday, February 11th. Citigroup reduced their price target on shares of DexCom from $660.00 to $630.00 in a research note on Friday, February 11th. Robert W. Baird reduced their price target on shares of DexCom from $625.00 to $560.00 in a research note on Friday, February 11th. Finally, Piper Sandler reduced their price target on shares of DexCom from $725.00 to $480.00 in a research note on Friday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, DexCom presently has an average rating of “Buy” and an average price target of $547.82.

In related news, Director Barbara Kahn sold 4,666 shares of the company’s stock in a transaction that occurred on Thursday, February 10th. The shares were sold at an average price of $442.35, for a total value of $2,064,005.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, February 14th. The shares were sold at an average price of $418.04, for a total transaction of $1,254,120.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,898 shares of company stock valued at $4,835,482. 0.41% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in DXCM. Natixis increased its stake in shares of DexCom by 74.8% during the 3rd quarter. Natixis now owns 133,349 shares of the medical device company’s stock worth $72,923,000 after purchasing an additional 57,052 shares during the last quarter. Gradient Investments LLC increased its stake in shares of DexCom by 19.6% during the 4th quarter. Gradient Investments LLC now owns 26,471 shares of the medical device company’s stock worth $14,214,000 after purchasing an additional 4,334 shares during the last quarter. Jefferies Group LLC increased its stake in shares of DexCom by 387.8% during the 3rd quarter. Jefferies Group LLC now owns 52,196 shares of the medical device company’s stock worth $28,544,000 after purchasing an additional 41,496 shares during the last quarter. CAPROCK Group Inc. increased its stake in shares of DexCom by 3.0% during the 4th quarter. CAPROCK Group Inc. now owns 3,738 shares of the medical device company’s stock worth $2,007,000 after purchasing an additional 110 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in shares of DexCom by 1.0% during the 4th quarter. New York State Teachers Retirement System now owns 113,317 shares of the medical device company’s stock worth $60,846,000 after purchasing an additional 1,172 shares during the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

NASDAQ DXCM opened at $408.58 on Friday. DexCom has a 52 week low of $318.45 and a 52 week high of $659.45. The company has a current ratio of 5.11, a quick ratio of 4.62 and a debt-to-equity ratio of 0.76. The stock has a market cap of $40.09 billion, a price-to-earnings ratio of 197.38, a price-to-earnings-growth ratio of 6.95 and a beta of 0.94. The company has a 50-day moving average price of $455.57 and a two-hundred day moving average price of $500.59.

Shares of DexCom are set to split on the morning of Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly issued shares will be issued to shareholders after the closing bell on Thursday, June 9th.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Read More

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.